TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 10:06:15 2024-04-19 am EDT			5-day change	1st Jan Change
0.25 ^EUR	-1.96%		-9.68%	+9.57%

Apr. 03	TME Pharma: Fast Track designation in glioblastoma	CF
Apr. 02	TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer	CI

NOXXON Pharma N.V. Announces Appointment of Bryan Jennings as Additional Statutory Director

December 15, 2021 at 12:00 pm EST

NOXXON Pharma N.V. announced that the extraordinary general meeting of shareholders held on December 15, 2021 at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands approved to appoint Bryan Jennings as additional statutory director of NOXXON Pharma N.V.

Latest news about TME Pharma N.V.

TME Pharma: Fast Track designation in glioblastoma	Apr. 03	CF
TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer	Apr. 02	CI
Invest Securities Keeps TME Pharma at Buy, Trims PT	Apr. 02	MT
TME PHARMA : Invest Securities slightly adjusts its target	Apr. 02	CF
TME Pharma: green light from the FDA to launch a ph.II trial	Mar. 05	CF
TME Pharma N.V. Announces FDA Clearance of Investigational New Drug Application for Nox-A12 Phase 2 Trial in Brain Cancer	Mar. 05	CI
TME Pharma: end of convertible bond program	Feb. 09	CF
TME Pharma Raises EUR1.5 Million to Buy Back Convertible Bonds	Feb. 09	MT
TME Pharma N.V. announced that it expects to receive ?1.479999 million in funding	Feb. 08	CI
TME Pharma On Track to Complete Clinical Trial Protocol for Brain Cancer Therapy by Q1	Jan. 10	MT
TME Pharma Announces Successful Advice Meeting with US Food and Drug Administration on Nox-A12 Development in Brain Cancer	Jan. 09	CI
TME Pharma N.V. announced that it has received ?2.7 million in funding	Dec. 13	CI
TME PHARMA : Invest Securities updates its target	Nov. 28	CF
TME Pharma: shares fall after capital increase	Nov. 27	CF
TME Pharma N.V. announced that it expects to receive ?2.7 million in funding	Nov. 23	CI
TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-27	CI
TME Pharma N.V. Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer	23-10-10	CI
TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting	23-09-22	CI
Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer	23-09-13	CI
TME Pharma N.V. Provides Positive Data Update on Best Response to Therapy with First Complete Response in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near- Complete Response	23-07-13	CI
TME Pharma N.V. Announces Positive 15-Month Survival Data from Gloria Expansion Arm Evaluating NOX-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma	23-06-28	CI
Appetite for Risk Surges	23-06-16
TME Pharma N.V. Receives Investigational New Drug Approval for NOX-A12 From the US FDA	23-06-15	CI
TME Pharma N.V. Provides Positive Clinical Update and 14-Month Survival Data from Gloria Expansion Arm Evaluating Nox-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma	23-05-25	CI
TME Pharma N.V. Auditor Raises 'Going Concern' Doubt	23-04-23	CI

Chart TME Pharma N.V.

Duration

Period

More charts

Company Profile

TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.

Sector

Biotechnology & Medical Research

Calendar

2024-04-23 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TME PHARMA N.V.	+9.57%	7.73M
IQVIA HOLDINGS INC.	-1.14%	41.35B
LONZA GROUP AG	+42.38%	40.38B
MODERNA, INC.	+3.47%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+2.78%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-23.80%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.37%	11.68B
MEDPACE HOLDINGS, INC.	+22.99%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.62%	11.15B

Other Biotechnology & Medical Research